Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.20 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 severe pneumonia.
Description: To determine the efficacy of ruxolitinib measured by overall survival
Measure: Overall survival Time: 28 days after registration into trialDescription: Assessment of the duration of ventilation support
Measure: Assessment of the duration of ventilation support Time: registration until 90 days after registration into trialDescription: Assessment of the extent of cytokine storm reduction (IL-6, CRP, ferritin)
Measure: cytokine storm Time: registration until 90 days after registration into trialDescription: To assess time on ICU
Measure: time on ICU Time: registration until 90 days after registration into trialDescription: To assess toxicity and safety of ruxolitinib treatment
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Time: registration until 90 days after registration into trialDescription: To assess the timeframe for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)
Measure: time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG) Time: registration until 90 days after registration into trialDescription: To assess pulmonary function (time point discharge from hospital) by CT scan
Measure: pulmonary function assessed by a CT scan Time: registration until 90 days after registration into trialDescription: To determine the efficacy of ruxolitinib measured by overall survival
Measure: overall survival Time: 90 days after registration into trial